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The primary targets for SARS-CoV infection are the epithelial cells in the respiratory and intestinal
tract. The angiotensin-converting enzyme 2 (ACE-2) has been identified as a functional receptor for
SARS-CoV. ACE-2 has been shown to be expressed at the apical domain of polarized Calu-3 cells.
In this report, interferon alfacon 1 was examined for inhibitory activities against SARS-CoV on
human lung carcinoma epithelial Calu-3 cell line and the other three African green monkey kidney
epithelial cell lines. Interferon alfacon 1 demonstrated significant antiviral activity in neutral red
uptake assay and virus yield reduction assay. The data might provide an important insight into the
mechanism of pathogenesis of SARS-CoV allowing further development of antiviral therapies for
treating SARS infections.
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Severe acute respiratory syndrome (SARS) is the first new infectious disease of this century
caused by a novel human corona virus (SARS-CoV) that leads to pulmonary pathological
features [1,2]. SARS, which originated from Southern China at the end of 2002, has a high
mortality and morbidity. Since then the disease had spread to more than 30 countries. By July
31, 2003, more than 8,000 SARS cases and nearly 800 SARS-related deaths were reported
around the world. Studies on the molecular evolution of SARS-CoV suggested that the virus
emerged from non-human sources [3]. The disease poses a new threat for respiratory medicine
and represents a challenge for antiviral drug development and administration [4,5].
The combination of ribavirin and corticosteroids was the most frequently administered antiviral
agent for SARS-CoV [6,7,8,9,10]. However, ribavirin at nontoxic concentrations has little in
vitro activity against SARS-CoV [11] and has many side effects [8]. An improved clinical
outcome was reported among SARS patients receiving early administration with Kaletra plus
ribavirin and corticosteroids [12]. We recently reported that ribavirin could enhance the SARS-
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CoV infectivity in BALB/c mice and our data did not support the use of ribavirin for treating
SARS patients [13]. Antibodies to the SARS-CoV spike protein have been shown to block
entry [14]. Small peptides derived from the heptad repeat (HR) regions of SARS-CoV S protein
have been shown to inhibit SARS-CoV infection by the interference of SARS-CoV fusion with
target cells [15,16]. SARS main protease, which is essential for the replication cycle of SARSCoV, has been a key target for developing anti-SARS drugs [17,18]. Antisense RNA and RNA
interference (RNAi) technologies have shown potential prospect in treating some severe
diseases [19] and has been considered as important candidate medicines in the treatment of
SARS infection. However, no clear evidence was demonstrated to support these clinical
observations. Therefore, development of new anti- SARS-CoV agents is urgently needed for
the treatment of SARS patients.
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Interferons are small, natural or synthetic protein and glycoprotein cytokines that are produced
by leucocytes, T-lymphocytes, and fibroblasts in response to infection and other biological
stimuli. Interferon can activate tumor-specific cytotoxic T-lymphocytes, which play an
important role in destroying foreign cells in the body. Interferons attach to special receptors
on the surface of cell membranes and induce transcription, which results in an anti-viral state
in the target cells. In 1957 researchers discovered that the immune system produced a substance
in response to a viral infection that acted as an anti-viral agent [20,21]. They called that
substance "interferon." Since then, recombinant DNA technology has provided a larger supply
of interferons and has allowed extensive research regarding interferon's therapeutic properties.
In a recent study, we evaluated a few compounds approved for therapeutic use in humans and
some in vitro inhibitors of SARS-CoV for inhibition in the mouse SARS-CoV replication
model. A hybrid interferon, interferon alpha (IFN-alpha) B/D, and a mismatched doublestranded (ds) RNA interferon inducer, Ampligen (poly I:poly C124), were shown to potently
inhibit virus titers in the lungs of infected mice [22]. In this report, we describe a cell-based
assay using SARS-CoV infection of human lung epithelial cells (Calu-3) and three African
green monkey kidney epithelial cell lines to evaluate a related compound, interferon alfacon
1 (IFN-alfacon 1, consensus interferon, Infergen™) against SARS-CoV.

Materials and methods
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Three African green monkey kidney epithelial cell lines, Vero 76, Vero E6, and MA104
(embryonic), were obtained from American Type Culture Collection (ATCC, Manassas, VA)
[23]. Vero 76 and MA104 cells were routinely grown in minimal essential medium (MEM)
supplemented with 10% heat-inactivated fetal bovine serum (FBS, Hyclone Laboratories,
Logan, UT) and Vero E6 cells were maintained in MEM supplemented with 10% FBS, 1%
MEM non-essential amino acids (Sigma-Aldrich Co., St. Louis, MO) and 1 mM of sodium
pyruvate (Sigma-Aldrich). Calu-3 cells are a human lung epithelial cell line originating from
a human pulmonary adenocarcinoma and, were grown in Dulbecco’s modified Eagle’s minimal
essential medium (DMEM) supplemented with 20% FBS (D-20) [24]. SARS-CoV, strain
Urbani (200300592), was obtained from the Centers for Disease Control (CDC, Atlanta, GA).
The strain was propagated and titrated in Vero 76 cells. For antiviral assays, the serum was
reduced to 2% and gentamicin added to the medium at a final concentration of 50 µg/ml. Stock
solutions of IFN-alfacon 1 (InterMune, Inc., Brisbane, CA) were made at a concentration of
15 µg/0.5 ml and stored at −20°C. IFN-alfacon 1 was solubilized in MEM for in vitro
experiments.
The neutral red (NR) uptake assay for determination of antiviral efficacy and compound
cytotoxicity was used for in vitro evaluation [13]. The cells were seeded to the 96-well tissue
culture plate (Corning Incorporated Costa, NY) in 0.1 ml at 2 × 105 cells/ml one day before,
and treated with IFN-alfacon 1 at the different concentrations. Then, the cells were infected
with SARS-CoV isolate at the multiplicity of infection (m.o.i) from 0.0007 to 0.003. Compound
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and virus were added in equal volumes (0.1 ml). The plates were incubated at 37°C for three
days until the cells in the virus control wells showed complete viral cytopathic effect (CPE)
by light microscopy. Each concentration of compound was assayed for inhibition of viral CPE
in triplicate and for cytotoxicity in duplicate. Six wells per plate were set aside as uninfected,
untreated cell controls and six wells per plate received virus only and represented controls for
virus replication.
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At three days post virus exposure, the cells were scored for percent CPE or for cytotoxicity by
microscopic observation. The values obtained were converted to percents of untreated,
uninfected controls. The 50% cell cytotoxic doses (CC50) and 50% virus inhibitory doses
(IC50), representing the putative concentration at which 50% of the monolayers would show
compound cytotoxicity or virus cytopathic effect, respectively, were estimated by regression
analysis. A selectivity index (SI) was calculated using the formula: SI = CC50/IC50. The activity
in the CPE assay was then verified spectrophotometrically by NR uptake assay on the same
plate. The NR assay was performed using a modified method of Cavenaugh et al. [25] as
described by Barnard et al. [13]. Briefly, NR dye was added to each well of the plate, and the
plate incubated for approximately 2 h at 37°C in the dark. The NR solution was removed from
the wells, rinsed and any remaining dye extracted using ethanol buffered with Sörenson's citrate
buffer. The plates were read at 405/540 nanometers (nm) wavelength with a microplate reader
(Opsys MR™, Dynex Technologies, Chantilly, VA). Absorbance values were expressed as
percents of untreated controls and IC50, CC50, and SI values were calculated as described
above.
Virus yield reduction assay is more sensitive assay to confirm the results of the NR uptake
assay. Infectious virus yield from the CPE inhibition assay were determined on the supernatant
from the test well as previously described [13]. Sample wells at each compound concentration
tested were pooled and titered in Vero 76 cells for infectious virus by CPE assay as previously
described by Barnard et al. [26]. A 90% reduction in virus yield (IC90) was then calculated by
linear regression analysis. This represented a one-log10 inhibition in titer when compared to
untreated virus controls.

Results
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We first examined the effect of IFN-alfacon 1 on the replication of SARS-CoV in Vero 76
cells at 37°C. IFN-alfacon 1 inhibited virus replication in a dose-dependent manner. IFNalfacon 1 had an IC50 of 0.14 ng/ml and CC50 of >100 ng/ml as determined by NR assay (Table
1). However, IFN-alfacon 1 did not always work in the Vero 76 cells. The activity against
SARS-CoV in Vero 76 cells was sporadic and appeared to be highly variable depending upon
the condition (age and health) of the host cells. The monolayers of Vero 76 cells had to be
rinsed gently to achieve valid NR assays. Then, IFN-alfacon 1 inhibition of virus replication
was further tested in Vero E6 cells and MA104 cells. IFN-alfacon 1 provided a complete
protection at the higher doses and a linear dose response at the lower part of the concentration
curve. IC50 was 2.62 ng/ml in Vero E6 cells and, 0.12 ng/ml in MA104 cells, respectively
(Table 1). IFN-alfacon 1 also inhibited SARS-CoV isolate with SI values ranging from >38 to
>833 (Table 1). The cytopathic effect in infected Calu-3 cells was not observed within three
days of infection.
The activity of IFN-alfacon 1 was further tested in a virus yield reduction assay. IFN-alfacon
1 reduced virus yields by 90% at 2.25 ng/ml in Vero 76 cells. IFN-alfacon 1 reduced virus
yields by 90% at 3.02 ng/ml in Vero E6 cells. IFN-alfacon 1 had an IC90 = 0.33 ng/ml in MA104
cells, which confirmed the activity demonstrated by NR assay (Table 2). SARS-CoV was found
to productively infect human bronchial epithelial Calu-3 cells; SARS-CoV-induced CPE was
initially observed in medium containing 20% FCS at day 8 and 2% FCS at day 4 [24]. Based
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on these observations, IFN-alfacon 1 was evaluated to test the inhibitory effect on plating of
SARS-CoV infection from the culture fluids of the infected Calu-3 cells. The supernatants
were kept frozen at −80°C until they were needed for assessing infectious viral titers by a
standard TCID50 assay with permissive Vero 76 cells, as described above. The activity of IFNalfacon 1 was confirmed by the virus yield reduction assay. IFN-alfacon 1 blocked viral
production after incubation for three days in comparison to mock-treated cells and reduced
virus yields by 90% at 0.046 ng/ml (Table 2). IFN-alfacon 1 inhibited SARS-CoV infection
in Calu-3 with SI value of 2173 (Table 2). We also verified that SARS-CoV can infect human
bronchial epithelial Calu-3 cells without causing significant cytopathic effects within 3 days
of infection (Table 3).

Discussion
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Interferons have been considered as the first line of defense against viral infections. Interferon
type I is divided into interferon-alpha (leukocyte interferon) produced by virus-infected
leukocytes and interferon-beta (fibroblast interferon) produced by virus-infected fibroblasts,
or virus-infected epithelial cells. Type 1 interferons (alpha/beta) have been shown to be
effective for treating patients with hepatitis type C (HCV) [27]. Alpha interferons, which not
only block the replication of several viruses but also activate the immune system, have also
been shown to be efficacious in treating hairy cell leukemia, malignant melanoma, and Kaposi's
sarcoma (an AIDS-related cancer) and interferon alpha was shown to effectively inhibit SARSCoV replication [28]. IFN-alfacon 1 is a non-naturally occurring, novel synthetic recombinant
type 1 interferon alpha developed by comparing the amino acid sequences of several natural
interferon-alpha subtypes and assigning the most frequently observed amino acid in each
corresponding position to generate a consensus molecule. IFN-alfacon 1 was also approved by
the US Food and Drug Administration as the new class of anti-HCV inhibitors. IFN-alfacon 1
is the only IFN tested in human trials. The re-treatment with IFN-alfacon 1 is effective therapy
for patients with chronic hepatitis C who have either not responded to previous interferon
therapy or relapsed after discontinuation of interferon therapy [29]. Paragas et al. reported that
the IFN-alfacon 1 had the anti-SARS-CoV activity only before infection in cell-based model
in vitro [30]. In this case, IFN-alfacon 1 most likely induces an antiviral state in the target cells,
which produce a cellular environment that is not suitable for viral replication. However, IFNalfacon 1 did not show activity when the cells were treated with IFN-alfacon 1 after infection
with SARS-CoV, suggesting that IFN-alfacon 1 might not directly block viral replication in
cells that are already infected [30]. Loutfy et al. demonstrated that IFN-alfacon 1 was combined
with corticosteroids, in a preliminary pilot study, to assess potential clinical benefit and safety
for SARS patients. This data suggested that IFN-alfacon 1 might function as an antiviral
therapeutic for the treatment of SARS patients [31].
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Epithelial cells are a primary barrier to infection by microorganisms entering the host via body
cavities. Epithelial cells are organized in a polarized fashion with two distinct membrane
domains, the apical and basolateral domains [32]. The primary targets for SARS-CoV infection
are the epithelial cells in the respiratory and intestinal tract. It has been reported that the
angiotensin-converting enzyme 2 (ACE-2) is the functional receptor for SARS-CoV [33].
Mossel et al. demonstrated that Vero E6, MA104 and Calu-3 cells expressed human ACE-2
on the apical membrance domain. The infection was initiated successfully from the apical, but
not from the basolateral side [23]. Tseng et al. published the first SARS-CoV in vitro replication
model using monolayers and polarized Calu-3 cells. The receptor for SARS-CoV is localized
on and mediates infection through the apical plasma membrane of respiratory epithelial cells
and SARS-CoV entry and release may be focused on the apical surface of these cells [24].
Except Calu-3 cells, no human respiratory epithelial cell lines have been shown as yet to support
SARS-CoV infection. In addition to searching for vaccines against SARS-CoV, it is important
for advancing our knowledge to understand how SARS-CoV interact with the polarized lung
Biochem Biophys Res Commun. Author manuscript; available in PMC 2009 June 20.
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epithelial cells and, to look for other approaches to block viral replication as a means of
chemotherapeutic control.
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We developed this simple assay system to screen one compound in Calu-3 cells, which had
been infected with SARS-CoV isolate, by virus yield reduction assay. Calu-3 cells were treated
with IFN-alfacon 1 and, inoculated with SARS-CoV isolate, the titers of infectious viral
particles in the supernatants harvested after infection for three days. We verified that SARSCoV can be propagated in Calu-3 cells in 3 days (Table 3). The human lung Calu-3 cell line
provides a useful model for evaluating efficacy and mechanisms of anti-SARS compounds
such as interferon. IFN-alfacon 1 was shown to be more active against SARS-CoV when tested
in human lung epithelial Calu-3 cells than in African green monkey epithelial cells (Table 2).
In our two assay systems, IFN-alfacon 1 demonstrated significant antiviral activity in neutral
red uptake assay and virus yield reduction assay. Our data might provide us an important insight
into the mechanism of pathogenesis of SARS-CoV and these properties might be
therapeutically advantageous.
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Table 1

Effect of interferon alfacon 1 on SARS-CoV replication in different cell lines in vitro
Cell linesa
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Vero 76
Vero E6
MA104
Calu-3

IC50b

Neutral red (NR) uptake assay (ng/ml)
CC50c

0.14 ± 0.07e
2.62 ± 2.06
0.12 ± 0.06
NDf

>100
>100
>100
>100

a

SId
>714
>38
>833
ND

Vero 76, Vero E6 and MA104 cells were seeded to the 96-well tissue culture plate in 0.1 ml at 2 × 105 cells/ml. Calu-3 cells were seeded in 0.2 ml at 4

× 105 cells/ml.
b

IC50: 50% inhibitory concentration.

c
CC50: 50% cytotoxic concentration.
d

SI: selectivity index.

e
Values are expressed as mean ± standard deviation.
f
Could not be determined, due to lack of virus-induced CPE in this cell line.
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Table 2

Effect of interferon alfacon 1 on SARS-CoV replication in different cell lines in vitro
Cell lines
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Virus yield reduction assay
IC (ng/ml)a

SIb

2.25 ± 3.67
3.02 ± 2.30c
0.33 ± 0.36
0.046 ± 0.011

44.4
33.3
303
2173

90

Vero 76
Vero E6
MA104
Calu-3
a

IC90: 90% inhibitory concentration.

b

SI: selective index (CC50/IC90), based on CC50 > 100 ng/ml.

c
Values are expressed as mean ± standard deviation.
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Table 3

Cytotoxicity of interferon alfacon 1 and virus yield after infection with Urbani isolate in different un-treated cell lines
in vitro

NIH-PA Author Manuscript

Cell lines

Cytotoxicitya
(%)

Virus yieldb
(log10CCID50 per 0.18 ml)

Vero 76
Vero E6
MA104
Calu-3

1.7 ± 2.9c
24.5 ± 21.5
18.9 ± 21.3
33.9 ± 8.9

4.5 ± 0.39
4.5 ± 0.075
5.2 ± 0.36
3.8 ± 0.76

a

Cytotoxicity of IFN-alfacon 1 at 100 ng/ml.

b

Average virus control titers.

c
Values are expressed as mean ± standard deviation.
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